BMS986036



NAME OF DRUG : BMS986036

ALSO KNOWN AS : BMS986036

LABORATORY : Bristol-MyersSquibb

STATUS AND ADVANCEMENT

Type of drug : PEG-FGF21

Clinical trials advancement : Initiating Phase 2b

Estimated time to market : 104 months.

LABORATORY ABSTRACT ON THE DRUG

BMS 986036 is a novel pegylated recombinant human fibroblast growth factor 21 analog

RECENT NEWS ON BMS986036

SOME PUBLICATIONS RELATED WITH BMS986036

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH BMS986036


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE